Adagene (ADAG) Investor Presentation - Slideshow

Financial Status and Collaborations - Adagene's cash position was $174 million as of December 31, 2021[6], and the company received $17.5 million upfront from Sanofi and a $3 million milestone payment from Exelixis in early 2022[6, 107] - Adagene has a technology licensing agreement with Sanofi potentially worth $2.5 billion[6, 101, 104, 105], including a $17.5 million upfront payment[6, 101, 105] - Adagene has a technology licensing agreement with Exelixis, including $11 million upfront and a $3 million milestone achieved[6, 101] Pipeline and Clinical Programs - Adagene has 3 wholly-owned clinical assets and 5 programs in IND-enabling studies[6] - Adagene plans to submit IND or equivalent filings for two new candidates in 2022[6, 7, 46, 50, 51] - Adagene has >50 programs in discovery phase[7, 10, 46, 48] - Adagene's ADG116 monotherapy dose escalation completed at 10 mg/kg, with dose expansion ongoing and escalation initiated at 15 mg/kg[17, 22] - Adagene's ADG126 has enrolled 25 patients in Phase 1b/2 trial as of May 26, 2022, with no DLTs up to 10 mg/kg[17, 27] Anti-CTLA-4 Programs - The global market for CTLA-4 inhibitors is estimated to reach $11.9 billion by 2035[11] - Ipilimumab monotherapy had 36% Grade 3/4 treatment-related adverse events (AEs) in the 10 mg/kg group versus 20% in the 3 mg/kg group[14] - ADG126 showed durable reductions in target lesions (>20%) in 2 heavily pretreated patients with cold tumors[29] ADG106 Program - ADG106 showed a 2-fold synergistic effect with toripalimab for immune activation in clinical PD biomarker analysis[39]